Drug class
Fibrate lipid-modifying agent; peroxisome proliferator-activated receptor alpha (PPARα) agonist
Mechanism of action
Activates PPARα, increasing lipoprotein lipase activity and fatty-acid oxidation and reducing hepatic production of triglyceride-rich lipoproteins, lowering triglycerides and modifying HDL levels.
General use cases
- Treatment of mixed dyslipidaemia and hypertriglyceridaemia in adults when dietary and lifestyle measures are inadequate and where ciprofibrate is authorised; monitor muscle and liver safety, particularly with statin co-administration
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
